This transcript has been edited for clarity.
Michelle L. O'Donoghue, MD, MPH: Hi. I'm Dr Michelle O'Donoghue. I'm here at ESC Congress 2022, which is now back in person here in Barcelona. It's been very hot. I'm joined by Dr Marco Valgimigli, who almost needs no introduction at this point as he's been a leader in the field of antiplatelet therapy. I'm really specifically thinking about duration.
One of the pieces of science that he presented here at ESC is a meta-analysis asking the question, how does aspirin monotherapy compare to P2Y12 inhibitor monotherapy? This is a very hot topic.
Marco Valgimigli, MD, PhD: Thank you, Michelle. It's wonderful to be here and to be interviewed in person. Last year, we did that remotely. You're correct. We put together individual patient data in a dataset, comparing aspirin vs any P2Y12 inhibitor. I think it's a more relevant question than DAPT duration because, at the end of the day, you will have a DAPT phase, which can be short or less short, and at the end, then you have to decide which of the two components to continue. That was the purpose of pulling this dataset together.
We have seven studies and more than 25,000 patients.
Managing Cardiovascular Risk in Type 2 Diabetes
Managing Cardiovascular Risk in Patients With Chronic Kidney Disease
Unstable Angina
Is Diabetes a Cardiovascular Risk Equivalent?
COMMENTARY
Should Aspirin Be the Second-Line Antiplatelet in CAD?
The PANTHER Meta-analysis
Michelle L. O'Donoghue, MD, MPH; Marco Valgimigli, MD, PhD
DisclosuresAugust 31, 2022
This transcript has been edited for clarity.
Michelle L. O'Donoghue, MD, MPH: Hi. I'm Dr Michelle O'Donoghue. I'm here at ESC Congress 2022, which is now back in person here in Barcelona. It's been very hot. I'm joined by Dr Marco Valgimigli, who almost needs no introduction at this point as he's been a leader in the field of antiplatelet therapy. I'm really specifically thinking about duration.
One of the pieces of science that he presented here at ESC is a meta-analysis asking the question, how does aspirin monotherapy compare to P2Y12 inhibitor monotherapy? This is a very hot topic.
Marco Valgimigli, MD, PhD: Thank you, Michelle. It's wonderful to be here and to be interviewed in person. Last year, we did that remotely. You're correct. We put together individual patient data in a dataset, comparing aspirin vs any P2Y12 inhibitor. I think it's a more relevant question than DAPT duration because, at the end of the day, you will have a DAPT phase, which can be short or less short, and at the end, then you have to decide which of the two components to continue. That was the purpose of pulling this dataset together.
We have seven studies and more than 25,000 patients.
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Michelle L. O'Donoghue, Marco Valgimigli. Should Aspirin Be the Second-Line Antiplatelet in CAD? - Medscape - Aug 31, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Michelle L. O'Donoghue, MD, MPH
Senior Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School; Associate Physician, Brigham and Women's Hospital, Boston, Massachusetts
Disclosure: Michelle L. O'Donoghue, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novartis; Janssen; CRICO; AstraZeneca; Amgen
Received research grants via Brigham and Women's Hospital from: Amgen; Novartis; AstraZeneca; Janssen; Intarcia; Merck; Pfizer
Received honoraria from: Novartis; AstraZeneca; Amgen; Janssen; Medscape
Prior grants in past 3 years: AstraZeneca (antiplatelet drug ticagrelor); GlaxoSmithKline (anti-inflammatory drugs no longer in development: losmapimod and darapladib); Merck (osteoporosis drug no longer in development: odanacatib); Amgen (osteoporosis drug romosozumab) Janssen (diabetes drug canagliflozin)
Current grants from: Novartis (lipid-lowering drug inclisiran); Amgen (lipid-lowering drug evolocumab; drug that lowers certain lipoprotein); AstraZeneca/Medimmune (drug that blocks inflammatory receptor) Consulting: Novartis (lipid-lowering drug); Janssen (education); CRICO AstraZeneca (data safety monitoring board for gout and cardiovascular drug); Amgen (drug that lowers certain lipoprotein)
Honoraria: Medscape Cardiology
Marco Valgimigli, MD, PhD
Professor, Deputy Chief, Cardiocentro Ticino Institute, Universita della Svizzera Italiana, Lugano, Switzerland
Disclosure: Marco Valgimigli, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Astra Zeneca
Serve(d) as a speaker or a member of a speakers bureau for: Astra Zeneca